GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Rainmed Medical Ltd (HKSE:02297) » Definitions » Cash Flow from Financing

Rainmed Medical (HKSE:02297) Cash Flow from Financing : HK$-14.59 Mil (TTM As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Rainmed Medical Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Jun. 2024, Rainmed Medical paid HK$0.00 Mil more to buy back shares than it received from issuing new shares. It received HK$10.66 Mil from issuing more debt. It paid HK$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received HK$0.00 Mil from paying cash dividends to shareholders. It spent HK$0.39 Mil on other financial activities. In all, Rainmed Medical earned HK$10.27 Mil on financial activities for the six months ended in Jun. 2024.


Rainmed Medical Cash Flow from Financing Historical Data

The historical data trend for Rainmed Medical's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rainmed Medical Cash Flow from Financing Chart

Rainmed Medical Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
11.29 776.13 134.82 -17.37

Rainmed Medical Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cash Flow from Financing Get a 7-Day Free Trial -4.60 139.20 3.68 -21.05 6.46

Rainmed Medical Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Rainmed Medical's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Rainmed Medical's Cash from Financing for the quarter that ended in Jun. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-14.59 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rainmed Medical  (HKSE:02297) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Rainmed Medical's issuance of stock for the six months ended in Jun. 2024 was HK$0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Rainmed Medical's repurchase of stock for the six months ended in Jun. 2024 was HK$0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Rainmed Medical's net issuance of debt for the six months ended in Jun. 2024 was HK$10.66 Mil. Rainmed Medical received HK$10.66 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Rainmed Medical's net issuance of preferred for the six months ended in Jun. 2024 was HK$0.00 Mil. Rainmed Medical paid HK$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Rainmed Medical's cash flow for dividends for the six months ended in Jun. 2024 was HK$0.00 Mil. Rainmed Medical received HK$0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Rainmed Medical's other financing for the six months ended in Jun. 2024 was HK$-0.39 Mil. Rainmed Medical spent HK$0.39 Mil on other financial activities.


Rainmed Medical Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Rainmed Medical's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Rainmed Medical Business Description

Traded in Other Exchanges
N/A
Address
No. 99, Jinji Lake Avenue, Building 31, Northeast District, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215000
Rainmed Medical Ltd is focused on the design, development, and commercialization of coronary angiography-derived fractional flow reserve systems and coronary angiography-derived index of microcirculatory resistance systems. The company's core products, the caFFR system and the caIMR system are medical devices used to evaluate the severity of myocardial ischemia arising from coronary artery stenosis and microvascular dysfunction, which are the underlying causes of coronary artery diseases (CAD). It operates in China and Other countries.
Executives
Huo Yunfei 2101 Beneficial owner
Zhou Bin
Zhong Guo Ping An Bao Xian Ji Tuan Gu Fen You Xian Gong Si
Xi Zang Jing Jia Qi Ye Guan Li You Xian Ze Ren Gong Si
Shang Hai Jing Lin Gu Quan Tou Zi Guan Li You Xian Gong Si
Shang Hai Jing Wu Tou Zi Zhong Xin You Xian He Huo
Shang Hai Jing Mai Run Qi Ye Guan Li Zhong Xin You Xian He Huo
Gong Qing Cheng Jing Cheng Yu Tou Zi Guan Li He Huo Qi Ye You Xian He Huo
Gong Qing Cheng Jing Lin Jing Jia Tou Zi Guan Li He Huo Qi Ye You Xian He Huo
Jing Lin Zi Ben Guan Li You Xian Gong Si
Shen Zhen Jing Lin Jing Ying Gu Quan Tou Zi Ji Jin He Huo Qi Ye You Xian He Huo
Shen Zhen Jing Hui Gu Quan Tou Zi Guan Li He Huo Qi Ye You Xian He Huo
Shang Hai Tong Xiang Hao Qian Qi Ye Guan Li He Huo Qi Ye You Xian He Huo
Xi Zang Jing Ning Qi Ye Guan Li You Xian Ze Ren Gong Si
Liu Li Rui

Rainmed Medical Headlines

No Headlines